Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Jonathan P Belk

Shankar Kumar

Richard W Dixon

Paul Robert Hinton

Yan Chen

Maria A Argiriadi

Carolyn A Cuff

Hua Ying

Terry L Melim

Michael Roguska

Emma Fung

Susan E Lacy

Chung-Ming Hsieh

Joan D Tyner

Chengbin Wu

Lorenzo Benatuil

Jennifer Maria Perez

Robert N Ziemann

Susan E Brophy

Edward B Reilly

Dagang Huang

Paul R Hinton

Bryan Tieman

James Scheffel

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.

Methods for transforming yeast

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

IL-12/p40 binding proteins

Growing community of inventors

Sterling, MA, United States of America

Jonathan P Belk